MGTX News and Press, MeiraGTx Holdings plc From 02/27/24

2024-02-27 04:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-02-15 08:23:45 ET Summary Positive results achieved in phase 1/2 MGT009 study using bota-vec for the treatment of patients with XLRP; Patients given this gene therapy achieved meaningful improvement of vision. Enrollment completed in ongoing phase 3 LUMEOS study, using b...

2024-02-13 08:31:06 ET More on MeiraGTx MeiraGTx signs asset purchase agreement for bota-vec collaboration with Janssen Seeking Alpha’s Quant Rating on MeiraGTx Historical earnings data for MeiraGTx Financial information for MeiraGTx Read the...

LONDON and NEW YORK, Feb. 13, 2024 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced the achievement of the first milestone under the asset purchase agreement the Company entered into with Janssen...

2023-12-21 12:18:35 ET Gainers: Infrared Cameras Holdings ( MSAI ) +195% . Mullen Automotive ( MULN ) +112% . Baijiayun Group Ltd ( RTC ) +33% . HeartBeam ( BEAT ) +31% . Triumph Group ( TGI ) +32% . TC BioPharm ( TCBP ) ...

2023-12-21 10:00:01 ET More on Health Care Select Sector SPDR XLV Likely Back To Outperforming XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector For further details see: Cassava Sciences, Myomo among healthcare movers

2023-12-21 08:15:23 ET MeiraGTx ( NASDAQ: MGTX ) said Thursday it signed an asset purchase agreement for the remaining interests in bota-vec, used for the treatment of XLRP, from Janssen Pharmaceuticals. The company has also signed a commercial supply agreement and a techno...

- MeiraGTx enters into an Asset Purchase Agreement related to botaretigene sparoparvovec (bota-vec, formerly AAV-RPGR) for the treatment of X-linked retinitis pigmentosa (XLRP) for a total of up to $415 million - MeiraGTx to receive $130 million in upfront and near-term milestone paymen...

2023-11-14 14:39:23 ET More on MeiraGTx MeiraGTx reports $30 million strategic investment from Sanofi Seeking Alpha’s Quant Rating on MeiraGTx Historical earnings data for MeiraGTx Financial information for MeiraGTx For further details see: ...

- Received strategic investment from Sanofi purchasing $30 million of ordinary shares of the Company at a price of $7.50 per share in October 2023 - Announced a right of first negotiation (ROFN) with Sanofi for the use of MeiraGTx’s Riboswitch gene regulation technology for c...